Skip to content
HowShorted

Coherus Oncology, Inc. short interest in 2021

In 2021, Coherus Oncology, Inc.'s disclosed short interest ran from 20.95% of shares outstanding on 15 Jan 2021 to 9.27% on 31 Dec 2021, a change of -11.68 percentage points. The year's high was 20.95% on 15 Jan 2021 and its low 8.89% on 15 Dec 2021, averaging 13.57% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.72 days on 29 Oct 2021. Full history: Coherus Oncology, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Coherus Oncology, Inc. in 2021

2021 in figures

Start of year
20.95% (15 Jan 2021)
End of year
9.27% (31 Dec 2021)
Change
-11.68 pp
High
20.95% (15 Jan 2021)
Low
8.89% (15 Dec 2021)
Average
13.57%
Highest days to cover
18.72 (29 Oct 2021)
SEC filings marked
8

Every report in 2021

Coherus Oncology, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 202120.95%12.36
29 Jan 202118.58%7.96
12 Feb 202117.97%9.18
26 Feb 202118.44%11.37results (8-K), 10-K filed
15 Mar 202118.65%9.21
31 Mar 202119.02%15.29
15 Apr 202118.44%16.21
30 Apr 202114.74%14.36
14 May 202113.95%14.0110-Q filed, results (8-K)
28 May 202113.22%12.29
15 Jun 202112.80%11.99
30 Jun 202112.56%11.87
15 Jul 202112.31%18.62
30 Jul 202112.22%17.27
13 Aug 202112.05%16.7610-Q filed, results (8-K)
31 Aug 202112.70%11.53
15 Sep 202111.19%14.78
30 Sep 20219.69%7.59
15 Oct 20219.83%13.66
29 Oct 20219.82%18.72
15 Nov 20219.17%9.1610-Q filed, results (8-K)
30 Nov 20219.30%14.33
15 Dec 20218.89%9.83
31 Dec 20219.27%8.98

See also: Coherus Oncology, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.